Drugs Made In America Acquisition Ordinary Shares Total Liabilities

Drugs Made In America Acquisition Ordinary Shares posts a total liabilities of $9.1M as of June 2026. That compares with $7.2M in the prior-year period — up 26.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Drugs Made In America Acquisition Ordinary Shares's total liabilities was $7.2M. The latest reading is $9.1M — a 26.9% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Drugs Made In America Acquisition Ordinary Shares's financial statement story. At $9.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for DMAA's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Drugs Made In America Acquisition Ordinary Shares's other metric pages and overview cover the third.